Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for WAT Browning and Insulin Sensitivity in Overweight Adults
NCT02524184Phase 4
Key facts
- Status
- Unknown
- Start
- Aug 2015
- Primary completion
- Sep 2016
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- sildenafil
- Conditions
- obesity
01
Overview
Phase 4, double-blind trial of sildenafil in obesity. Primary endpoint: Browning of white adipose tissue at 7 days. Status: unknown.
02
Design
- Study design
- Double-blind
03
Who it enrols
Overweight males aged 20-30 with normal glucose tolerance and no cardiovascular or infectious diseases.
04
Endpoints
Primary
Browning of white adipose tissue
Secondary
Improvement of insulin sensitivity
Beyond the preview
Go deeper on NCT02524184.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02524184.